Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)

American Journal of Ophthalmology

Volumn 186, Issue , 2018, Pages 116-127

  Serle, Janet B ^a   Katz, L Jay ^b   McLaurin, Eugene ^c   Heah, Theresa ^d   Ramirez Davis, Nancy ^d   Usner, Dale W ^e   Novack, Gary D ^f,g   Kopczynski, Casey C ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c Total Eye Care PA   (United States)

^d and Durham   (United States)

^e SDC Materials   (United States)

^f PHARMALOGIC DEVELOPMENT INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NETARSUDIL; PROSTAGLANDIN; RHO KINASE; TIMOLOL MALEATE; AR-13324; BENZOIC ACID; BETA ALANINE; EYE DROPS; TIMOLOL;

ADULT; AGED; ARTICLE; BLURRED VISION; CHEMOSIS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISEASE; EYE IRRITATION; EYE PAIN; EYELID EDEMA; EYELID ERYTHEMA; FEMALE; HEADACHE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LACRIMAL GLAND DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; NEUROLOGIC DISEASE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SOFT TISSUE DISEASE; THORAX DISEASE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHILD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BENZOATES; BETA-ALANINE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; RHO-ASSOCIATED KINASES; TIME FACTORS; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85038842758     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2017.11.019     Document Type: Article

References (29)

1. Alward, W.L., Medical management of glaucoma. N Engl J Med 339:18 (1998), 1298–1307.
2. Casson, R.J., Chidlow, G., Wood, J.P., Crowston, J.G., Goldberg, I., Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol 40:4 (2012), 341–349.
3. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:4 (2000), 429–440.
4. Heijl, A., Leske, M.C., Bengtsson, B., et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 120:10 (2002), 1268–1279.
5. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al., Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:6 (2002), 701–713.
6. Lichter, P.R., Musch, D.C., Gillespie, B.W., et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108:11 (2001), 1943–1953.
7. Garway-Heath, D.F., Crabb, D.P., Bunce, C., et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 385:9975 (2014), 1295–1304.
8. European Glaucoma Society, Terminology and Guidelines for Glaucoma. 4th ed., 2014, PubliComm, Savona, Italy.
9. Boland, M.V., Chang, D.S., Frazier, T., Plyler, R., Friedman, D.S., Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The Automated Dosing Reminder Study. JAMA Ophthalmol 132:7 (2014), 838–844.
10. Robin, A.L., Novack, G.D., Covert, D.W., Crockett, R.S., Marcic, T.S., Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 144:4 (2007), 533–540.
11. Kopczynski, C.C., Epstein, D.L., Emerging trabecular outflow drugs. J Ocul Pharmacol Ther 30:2-3 (2014), 85–87.
12. Tian, B., Kaufman, P.L., Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp Eye Res 80:2 (2005), 215–225.
13. Tokushige, H., Inatani, M., Nemoto, S., et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 48:7 (2007), 3216–3222.
14. Honjo, M., Inatani, M., Kido, N., et al. Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes. Arch Ophthalmol 119:8 (2001), 1171–1178.
15. Wang, R.-F., Williamson, J.E., Kopczynski, C., Serle, J.B., Effect of 0.04% AR-13324, a ROCK and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma 24:1 (2015), 51–54.
16. Rao, P.V., Pattabiraman, P.P., Kopczynski, C., Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res 158 (2017), 23–32.
17. Sturdivant, J.M., Royalty, S.M., Lin, C.W., et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett 26:10 (2016), 2475–2480.
18. Lin, C.W., Sherman, B., Moore, L.A., et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther, 2017, 10.1089/jop.2017.0023.
19. Kiel, J.W., Kopczynski, C., Effect of AR-13324 on episcleral venous pressure in Dutch Belted rabbits. J Ocul Pharmacol Ther 31:3 (2015), 146–151.
20. Sit, A.J., Kazemi, A., McLaren, J.W., Kopczynski, C., Heah, T.G., Novack, G.D., The effects of netarsudil ophthalmic solution on aqueous humor dynamics in humans. Invest Ophthal Vis Sci, 58, 2017 ARVO E-Abstract 2112.
21. Bacharach, J., Dubiner, H.B., Levy, B., Kopczynski, C.C., Novack, G.D., AR-13324-CS202 Study Group. Double-masked, randomized, dose-response study of AR-13324 vs. latanoprost in patients with elevated intraocular pressure. Ophthalmology 122:2 (2015), 302–307.
22. Sherwood, M.B., Craven, E.R., Chou, C., et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 124:9 (2006), 1230–1238.
23. Hughes, B.A., Bacharach, J., Craven, E.R., et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma 14:5 (2005), 392–399.
24. Stone, J.L., Robin, A.L., Novack, G.D., Covert, D., Cagle, G.D., An objective evaluation of eye-drop instillation in glaucoma patients. Arch Ophthalmol 127:6 (2009), 732–736.
25. Weinreb, R.N., Kaufman, P.L., The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 50:4 (2009), 1497–1505.
26. Hedman, K., Alm, A., A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 10:2 (2000), 95–104.
27. Schehlein, E.M., Novack, G.D., Robin, A.L., New classes of glaucoma medications. Curr Opin Ophthalmol 28:2 (2017), 161–168.
28. Hu, E., Lee, D., Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges. Expert Opin Ther Targets 9:4 (2005), 715–736.
29. Raizman, M.B., Hamrah, P., Holland, E.J., et al. Drug-induced corneal epithelial changes. Surv Ophthalmol 62:3 (2017), 286–301.